Adalimumab for the treatment of ankylosing spondylitis

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 6, 2007, Pages 831-838

  Sieper, Joachim ^a   Rudwaleit, Martin ^a   Braun, Jürgen ^b  

^a Medical Department   (Germany)

^b RHEUMAZENTRUM RUHRGEBIET   (Germany)

Author keywords

Adalimumab; Ankylosing spondylitis; Early treatment; Long term treatment

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ANKYLOSING SPONDYLITIS; ARTICLE; CANCER; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEMYELINATION; DISEASE ACTIVITY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; INFECTION; INJECTION SITE REACTION; LONG TERM CARE; LUPUS LIKE SYNDROME; META ANALYSIS; PATHOGENESIS; PHYSIOTHERAPY; PREVALENCE; SACROILIITIS; SYSTEMATIC REVIEW; TUBERCULOSIS; DRUG ANTAGONISM; IMMUNOLOGY; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; HUMANS; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34247847971     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.6.831     Document Type: Article

References (51)

1. SIEPER J, RUDWALEIT M, KHAN MA, BRAUN J: Concepts and epidemiology of spondyloarthritis. Best Pract. Res. Clin. Rheumatol. (2006) 20(3):401-417.
2. ZOCHLING J, VAN DER HEIJDE D, BURGOS-VARGAS R et al.: ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann. Rheum. Dis. (2006) 65(4):442-452.
3. HAIBEL H, RUDWALEIT M, BRAUN J, SIEPER J: Six months open label trial of leflunomide in active ankylosing spondylitis. Ann. Rheum. Dis. (2005) 64(1):124-126.
4. VAN DENDEREN JC, VAN DER PAARDT M, NURMOHAMED MT et al.: Double-blind, randomised, placebo-controlled study of leflunomide in the treatment of active ankylosing spondylitis. Ann. Rheum. Dis. (2005) 64(12):1761-1764.
5. HAIBEL H, BRANDT HC, SONG IH et al.: No efficacy of subcutaneous methotrexate in active ankylosing spondylitis - a 16 weeks open label trial. Ann. Rheum. Dis. (2007) 66(3):419-421
6. HAIBEL H, RUDWALEIT M, LISTING J, SIEPER J: Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann. Rheum. Dis. (2005) 64(2):296-298.
7. CHEN J, LIU C: Methotrexate for ankylosing spondylitis. Cochrane Database Syst. Rev. (2004) (3):CD004524.
8. CHEN J, LIU C: Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst. Rev. (2005) (2):CD004800.
9. BRAUN J, ZOCHLING J, BARALIAKOS X et al.: Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomized controlled trial. Ann. Rheum. Dis. (2006) 65(9):1147-1153.
10. BRAUN J, DAVIS J, DOUGADOS M et al.: First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann. Rheum. Dis. (2006) 65(3):316-320.
11. MAKSYMOWYCH WP: Ankylosing spondylitis-at the interface of bone and cartilage. J. Rheumatol. (2000) 27(10):2295-2301.
12. BRAUN J, BOLLOW M, EGGENS U et al.: Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum. (1994) 37(7):1039-1045.
13. BRAUN J, BOLLOW M, NEURE L et al.: Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. (1995) 38(4):499-505.
14. BOLLOW M, FISCHER T, REISSHAUER H et al.: Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis- cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann. Rheum. Dis. (2000) 59(2):135-140.
15. BRAUN J, BRANDT J, LISTING J et al.: Treatment of active ankylosing spondyliris with infliximab: a randomised controlled multicentre trial. Lancet (2002) 359(9313):1187-1193.
16. VAN DER HEIJDE D, DIJKMANS B, GEUSENS P et al.: Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. (2005) 52(2):582-591.
17. DAVIS JC, Jr, VAN DER HEIJDE D, BRAUN J et al.: Recombinant human rumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. (2003) 48(11):3230-3236.
18. CALIN A, DIJKMANS BA, EMERY P et al.: Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann. Rheum. Dis. (2004) 63(12):1594-1600.
19. BRAUN J, LANDEWE R, HERMANN KG et al.: Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum. (2006) 54(5):1646-1652.
20. RUDWALEIT M, BARALIAKOS X, LISTING J et al.: Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. Ann. Rheum. Dis. (2005) 64(9):1305-1310.
21. BRAUN J, BARALIAKOS X, BRANDT J et al.: Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) (2005) 44(5):670-676.
22. BARALIAKOS X, BRANDT J, LISTING J et al.: Outcome of patients with active ankylosing spondylitis after 2 years of therapy with etanercept - clinical and magnetic resonance imaging data. Arthritis Rheum. (2005) 53(6):856-863.
23. SIEPER J, BRAUN J: Anti-TNF agents for the treatment of spondyloarthropathies. Expert Opin. Emerg. Drugs (2002) 7(2):235-246.
24. BRAUN J, BARALIAKOS X, LISTING J, SIEPER J: Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. (2005) 52(8):2447-2451.
25. VAN DER HEIJDE D, DA SILVA JC, DOUGADOS M et al.: Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann. Rheum. Dis. (2006) 65(12):1572-1577.
26. SALFELD J, KAYMAKCALAN Z, TRACEY D, ROBERT A, KAMEN R: Generation of fully human anti-TNF antibody D2E7. Arthritis Rheum. (1998) 41:S57.
27. LEE SH, KAVANAUGH A: Adalimumab for the treatment of rheumatoid arthritis. Therapy (2005) 2:13-21.
28. GEORGOPOULOS S, PLOWS D, KOLLIAS G: Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. J. Intlamm. (1996) 46(2):86-97.
29. GRANNEMANN RG, ZHANG Y, NOETERSHEUSER PA: Pharmocokinetic/ pharmacodynamic relationships of adalimumab in rheumatoid arthritis patients during Phase II/III clinical trials. Arthritis Rheum. (2003) 48:S140.
30. KAYMAKCALAN A, CUSH JJ, KAMEN R, SALFELD J: Comparison of adalimumab, infliximab, and etanercept in the prevention of polyarthritis in a transgenic murine model of rheumatoid arthritis. Arthritis Rheum. (2002) 46:S304.
31. GARRETT S, JENKINSON T, KENNEDY LG et al.: A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J. Rheumatol (1994) 21(12):2286-2291.
32. VAN DER HEIJDE D, BELLAMY N, CALIN A et al.: Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J. Rheumatol. (1997) 24(11):2225-2229.
33. ANDERSON JJ, BARON G, VAN DER HEIJDE D, FELSON DT, DOUGADOS M: Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. (2001) 44(8):1876-1886.
34. BRANDT J, LISTING J, SIEPER J et al.: Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann. Rheum. Dis. (2004) 63(11):1438-1444.
35. HAIBEL H, RUDWALEIT M, BRANDT HC et al.: Adalimumab reduces spinal symptoms in active ankylosing spondylitis - clinical and magnetic resonance imaging results of a fifty-two week open label trial. Arthritis Rheum. (2006) 54:678-681.
36. HAIBEL H, BRANDT HC, BARALIAKOS X et al.: Long-term efficacy and safety of adalimumab in the treatment of active ankylosing spondylitis: Results of an open-label 2-year trial. Ann. Rheum. Dis. (2006) 65 (Suppl. II; abstract THU0335):218.
37. VAN DER HEIJDE D, KIVITZ A, SCHIFF M et al.: Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2006) 54:2136-2146.
38. APPEL H, KUHNE M, SPIEKERMANN S et al.: Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum. (2006) 54(9):2845-2851.
39. RUDWALEIT M, LISTING J, BRANDT J, BRAUN J, SIEPER J: Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann. Rheum. Dis. (2004) 63(6):665-670.
40. VAN DER HEIJDE D, KIVITZ A, SCHIFF M et al.: Treatment with adalimumab reduces signs and symptoms and induces partial remission in patients with ankylosing spondylitis - 1-year results from ATLAS. Arthritis Rheum. (2006) 54:S792.
41. VAN DER HEIJDE D, LUO MP, WORDSWORTH P et al.: Adalimumab improves physcial functioning and work productivity in ankylosing spondylitis patients: results from ATLAS. Arthritis Rheum. (2006) 54:S99.
42. SCHIFF MH, BURMESTER GR, KENT JD et al.: Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann. Rheum. Dis. (2006) 65(7):889-894.
43. FELDTKELLER E, KHAN MA, VAN DER HEIJDE D, VAN DER LINDEN S, BRAUN J: Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol. Int. (2003) 23(2):61-66.
44. VAN DER LINDEN S, VALKENBURG HA, CATS A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. (1984) 27(4):361-368.
45. RUDWALEIT M, VAN DER HEIJDE D, KHAN MA, BRAUN J, SIEPER J: How to diagnose axial spondyloarthritis early. Ann. Rheum. Dis. (2004) 63(5):535-543.
46. RUDWALEIT M, KHAN MA, SIEPER J: The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum. (2005) 52(4):1000-1008.
47. HAIBEL H, RUDWALEIT M, HELDMANN F et al.: Efficacy of adalimumab in the treatment of preradiographic axial spondyloarthritis: results of a 12-week, randomized controlled trial. Arthritis Rheum. (2006) 54(Suppl.):Late breaking abstract. American College of Rheumatology Annual Scientific Meeting. Washington, DC, USA (10-15 November 2006).
48. LANGLEY R, LEONARDI C, TOTH D: Long-term safety and efficacy of adalimumab in the tretament of moderate to severe chronic plaque psoriasis (Abstr.) J. Am. Acad. Dermatol. (2005) 52:203.
49. HANAUER SB, SANDBORN WJ, RUTGEERTS P et al.: Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology (2006) 130(2):323-333; quiz 591.
50. BRAUN J, LISTING J, DAVIS J et al.: Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-TNFα agent. Arthritis Rheum. (2007) (In Press).
51. GUIGNARD S, GOSSEC L, SALLIOT C et al.: Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthroparhy: a retrospective study. Ann. Rheum. Dis. (2006) 65(12):1631-1634.